Risk Stratification of COVID-19 Patients Discharged From the Emergency Department

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

742 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-10

Study Completion Date

2021-02-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Risk stratification of COVID-19 patients is essential to define their appropriate treatment setting. So far, available studies have focused on morbidity and mortality prediction in patients admitted to hospital. In the Emergency Department (ED), decision on home discharge versus hospital admission for COVID-19 is cumbersome. While facing a dramatic second wave of SARS-CoV-2, shortage of hospital beds has further increased the challenge.

The present study will prospectively evaluate the clinical outcomes of patients discharged from the ED. Stratification will be based on a composite of demographic, clinical and lung imaging variables. Results will be used to develop standardized decision rules for safe home discharge of patients with COVID-19 evaluated in the ED.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED

NCT04682093

Covid19

UNKNOWN

Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED

NCT05465824

COVID-19

COMPLETED

COVID-19 Impact on the Lombardy Region's Emergency System

NCT04669925

Covid19

COMPLETED

Predicting Death and ICU Admission in COVID-19 Patients in ED

NCT04371562

COVID

COMPLETED

Application of Machine Learning Based Approaches in Emergency Department to Support Clinical Decision Managing SARS-CoV-2 Infected Patients

NCT04825301

Covid19

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with inclusion criteria and without exclusion criteria, evaluated in the participating EDs, will be enrolled in the study. Patients will undergo standard medical evaluation by the attending physician(s), following local guidelines and best medical practice, independent of participation to the study.

The following data will be recorded, when available:

* Demographic/clinical: age, gender, symptoms (type, time from onset), comorbidities, Glasgow Coma Scale score, respiratory rate, peripheral oxygen saturation
* Biochemical: urea, creatinine, C-reactive protein, procalcitonin, lactate dehydrogenase, white blood cell count, lymphocyte count, d-dimer
* Lung ultrasonography: site/type of B lines, consolidations, pleural effusion
* Radiology: chest X-ray result, chest CT result

Upon discharge, patients will be encouraged to contact emergency medical services or return the ED if needed, in case of clinical worsening.

The following endpoint will be assessed at 30 days after ED discharge, through standardized telephone interview and healthcare/other database query: any further hospital admission (for COVID-19 or other disease), death (for COVID-19 or other disease), respiratory failure/ventilation/intensive care admission (only for hospitalized COVID-19 patients).

Data analysis will focus on the outcome incidence in the study cohort, stratified by a composite of demographic/clinical, biochemical and imaging variables. A key stratification tool will be the 4C mortality score (BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3339). Additional integration of study variables will be evaluated to improve stratification and prediction.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

integrated clinical evaluation

30-day follow-up (telephone/database query) to define outcome Patients will receive standard care, independent of study participation.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

lung ultrasonosgraphy chest radiography (standard care, clinical decision) blood testing (standard care, clinical decision)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* symptomatic COVID-19 confirmed by treating physician
* positive nasopharyngeal swab for SARS-CoV-2 (performed during the ED visit or within last 14 days)
* First ED visit for suspected or confirmed COVID-19 (within last 30 days)
* Home discharge from ED based on treating physician's or patient's decision

Exclusion Criteria

* Age \<18 years
* Nursing home resident
* Already on home oxygen therapy
* Previous ED visit for suspected or confirmed COVID-19 (within last 30 days)
* Informed consent denial
* Follow-up not feasible

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No